Overview: Glycophorin Flow Cytometry TestIntroduction: The Glycophorin Flow Cytometry Test detects glycophorin markers to diagnose erythroid leukemia, causing fatigue or anemia. Aligned with 2023 ASH guidelines, it uses flow cytometry for high specificity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in hematology for patients with suspected erythroid leukemia.
Other Names: Glycophorin Flow Assay, Erythroid Marker Test.
FDA Status: Laboratory-developed test (LDT), meeting hematology standards for diagnostic accuracy.
Historical Milestone: Glycophorin testing began in the 1990s with leukemia research. Flow cytometry emerged in the 2000s, improving accuracy for erythroid marker detection.
Purpose: Diagnoses erythroid leukemia, guides treatment, and monitors glycophorin markers in patients with fatigue or anemia.
Test Parameters: 1. Glycophorin
Pretest Condition: No fasting required. Collect whole blood or bone marrow at any time. Report symptoms like fatigue or anemia, and list medications.
Specimen: 2-5 mL whole blood (EDTA) or 2-5 mL bone marrow (EDTA). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fatigue, anemia, or history of erythroid leukemia. Include current medications, especially chemotherapeutics.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for cancer therapy.
Procedural Considerations: Uses flow cytometry to detect glycophorin markers. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Poor sample quality or low cell yield can affect results. Non-malignant conditions may express glycophorin.
Clinical Significance: Positive glycophorin expression suggests erythroid leukemia, prompting treatment. Negative results may require additional marker testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation.
Additional Supporting Tests: Bone marrow biopsy, other flow cytometry markers, or cytogenetic testing to confirm erythroid leukemia.
Test Limitations: Non-specific expression may occur in non-malignant conditions. Results require clinical correlation.
References: ASH Leukemia Guidelines, 2023; Blood, Arber DA, 2022.
